Reimbursed Care Access in Marshall Islands

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Marshall Islands’ Prohibited Drugs (Prohibition and Control) Act 1987 (as amended) is the primary statutory framework controlling narcotics and psychotropic substances in the country; psychedelics such as psilocybin are not documented as having an authorized medical/reimbursement pathway under that Act. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record of MDMA being licensed for therapeutic programs or reimbursed by Marshall Islands health schemes; access would only be possible inside formally approved clinical research subject to national laws. #

Esketamine (the S‑enantiomer nasal product approved in some countries for treatment‑resistant depression) has no publicly available record of national marketing authorization, certified facility program, or reimbursement in the Marshall Islands; therefore it is not available as a reimbursed treatment locally. Ketamine derivatives and related centrally acting anaesthetics are controlled under national narcotics legislation, and any importation/medical use would be governed by the Prohibited Drugs (Prohibition and Control) Act and implementing regulations. Practically, approved esketamine products (where available abroad) require certified administration programs and are rarely available in small Pacific jurisdictions without specific import/registration action by the national health authorities. # #

Ketamine is recognized internationally as an essential anaesthetic and analgesic and is commonly controlled domestically while permitted for legitimate medical uses; in the Marshall Islands the national prohibited‑drugs framework governs its control but allows use under medical prescription/medical practice rather than as an over‑the‑counter or recreational product. Clinical use of ketamine for anaesthesia and emergency medicine is the established pathway (not a reimbursed psychedelic‑therapy program). Specific reimbursement arrangements (public insurance coverage or formulary listing) for ketamine infusions for psychiatric indications (e.g., off‑label treatment‑resistant depression) are not documented in official Marshall Islands legislation or health ministry publications; therefore, psychiatric uses — if provided — would be off‑label, delivered case‑by‑case in clinical settings and are unlikely to be reimbursed by domestic public health financing without a defined national program. The controlling statute for narcotics and psychotropic substances is the Prohibited Drugs (Prohibition and Control) Act 1987 and subsequent amendments which provide the legal framework for permitted medical use and regulation. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public record that DMT has an authorized therapeutic/reimbursed pathway in the Marshall Islands; possession, supply or manufacture outside authorized medical/research contexts would be prohibited under the country’s prohibited drugs legislation. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. No official medical programs or reimbursement mechanisms for 5‑MeO‑DMT are documented in Marshall Islands law or health ministry resources. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of regulated medical or reimbursed ibogaine treatment provision in the Marshall Islands. Access would be limited to sanctioned clinical research if any local approvals were obtained. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT/other controlled tryptamines used in ayahuasca would be subject to prohibition unless provided under an approved research or tightly regulated medical program. No national legal pathway for ritual or medical ayahuasca use is documented. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline and mescaline‑containing cacti are not documented as having a lawful medical or reimbursed therapeutic pathway in the Marshall Islands’ statutory framework. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel/phenethylamine hallucinogens (including the 2C family) are not recognized for medical reimbursement or routine clinical use in the Marshall Islands. #